PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Cytocentrics

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Cytocentrics Presents The CytoPatch™2 Automated Patch Clamp - Cytocentrics Bioscience GmbH, inventors of Cytocentering technology for automated patch clamp, is proud to announce the release of the second generation GLP compliant CytoPatch™ instrument, the CytoPatch2 - Cytocentrics.com
Cytocentrics Presents The CytoPatch™2 Automated Patch Clamp

 

NewswireToday - /newswire/ - Rostock, Mecklenburg-Vorpommern, Germany, 2013/03/04 - Cytocentrics Bioscience GmbH, inventors of Cytocentering technology for automated patch clamp, is proud to announce the release of the second generation GLP compliant CytoPatch™ instrument, the CytoPatch2 - Cytocentrics.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The CytoPatch2 builds on the technical success of the original CytoPatch™ system and is the first fully automated patch clamp system that is a viable alternative to manual patch clamp. Designed to closely mimic manual patch clamp processes, the CytoPatch2 generates the same high quality data as an experienced electrophysiologist working manually, and offers the broadest range of protocol flexibility of any available automated patch clamp system, making it ideal for researchers interested in ion channel biophysical characterisation and pharmacology.

Because the CytoPatch2 matches manual patch clamp with respect to data quality, users can fully benefit from the three R’s of automation without compromise. Reproducibility of data quality is gained by taking human subjectivity out of the patch process, Robustness of an assay is improved with the CytoPatch2 monitoring every step in the patch process and ensuring user-definable quality control criteria are met, and Reliability of the process is ensured by the fully integrated nature of the system components in the CytoPatch2. Additionally, by recording from two cells simultaneously, the CytoPatch2 offers double the throughput compared to manual patch clamp, and combined with walk-away operation, the addition of the CytoPatch2 into any patch clamp laboratory guarantees a significant increase in productivity.

By combining the microfluidic Cytocentering technology with a sophisticated liquid handling system and an all new digital amplifier with both voltage- and current clamp capabilities, the CytoPatch2 can record whole cell and single channel currents, and works equally well for voltage gated ion channels (constant perfusion mode) and ligand gated ion channels (fast solution exchange, <4ms compound wash-in, <10ms wash-out). The microfluidic scale of the patch consumable, which incorporates a glass patch pipette, means that the system requires very low numbers of cells (150 cells per capture), low volumes of compound and works with a wide variety of cell types, including cell lines, stem cells and derivatives such as cardiomyocytes, and primary cells such as chondrocytes and smooth muscle cells.

The WorkFlow Manager software package enables either a single, or group of, CytoPatch2 unit(s) to function as an effective screening system for CRO and Pharmaceutical company laboratories in areas such as cardiac safety testing and lead optimisation. And with the addition of two new software packages, The Assay Designer, and The Cockpit, it has never been easier to create new patch protocols and to interact with the CytoPatch2 in real time, making the CytoPatch2 an ideal research or assay development tool.

Dr Thomas Knott, CEO and founder of Cytocentrics, said “We are extremely excited about the release of the CytoPatch2. It is the result of many man-years of research and development and there is now a system available to our customers that really viable alternative to manual patch clamp. Matched with our (Cytocentrics’) continuing commercial development we are confident that Cytocentering technology and the CytoPatch2 has the potential to replace manual patch clamp in the majority of cases.”

About Cytocentrics

Cytocentrics Bioscience GmbH (cytocentrics.com) is a team of scientists, engineers and business professionals who apply our expertise to support our customers by supplying cutting edge automated patch clamp systems, ion channel cell lines, patch clamp reagents and ion channel screening services. Our wholly owned subsidiary, Cytocentrics BV, is a micro- and nano-technology service provider offering foundry service, design consultancy, prototyping and production of MEMS/MST (MicroElectroMechanical Systems / MicroSystemsTechnology) products for Original Equipment Manufacturer clients in the Life Science, Medical Devices and Diagnostics industries.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Cytocentrics

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Cytocentrics Presents The CytoPatch™2 Automated Patch Clamp

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Minka Dijkstra - Cytocentrics.com 
+31 408515530 info[.]cytocentrics.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Cytocentrics securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Cytocentrics / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® System
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization
Sugar Element of Keratan Sulfate Halts the Progress of Emphysema Finds RIKEN
Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada
FDA Extends Review of Application for OCREVUS™ (Ocrelizumab)
MDxHealth Announces AceCGT Life Science Limited as the Exclusive Distributor for SelectMDx in Hong Kong and Macao China
Pulse Certified As A Level Four Multichannel Content Agency by Veeva Systems
BD Launches Advanced Prefillable Syringe for Higher Volume Injection of Biologics
Sartorius Announces Expansion of Sartorius Stedim Cellca
Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
BD Integrating Technology, Expertise and Services to Provide Comprehensive Medication Management
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  1Click Games

Visit  Intrinsic Executive Search Ltd





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)